tradingkey.logo

tradingkey.logo
怜玢


Prothena Corporation PLC

PRTA
りォッチリストに远加
8.160USD
-0.070-0.85%
終倀 11-13 16:00ET
418.93M時䟡総額
損倱額盎近12ヶ月PER

Prothena Corporation PLCに぀いお 䌁業名

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Prothena Corporation PLC プロフィヌル


䌁業コヌドPRTA
䌚瀟名Prothena Corporation PLC
䞊堎日Dec 21, 2012
最高経営責任者「CEO」Kinney (Gene G)
埓業員数163
蚌刞皮類Ordinary Share
決算期末Dec 21
本瀟所圚地77 Sir John Rogerson's Quay, Block C
郜垂DUBLIN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Ireland
郵䟿番号D02 VK60
電話番号35312362500
りェブサむトhttps://www.prothena.com/
䌁業コヌドPRTA
䞊堎日Dec 21, 2012
最高経営責任者「CEO」Kinney (Gene G)

Prothena Corporation PLCの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Mr. Michael Isaacs
Mr. Michael Isaacs
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
35.74K
-36.59%
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Ms. Annie Kingston
Ms. Annie Kingston
Chief Strategy Officer
Chief Strategy Officer
--
--
Dr. Chad J. Swanson, Ph.D.
Dr. Chad J. Swanson, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. William H. Dunn, Jr., M.D.
Dr. William H. Dunn, Jr., M.D.
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Mr. Michael Isaacs
Mr. Michael Isaacs
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
35.74K
-36.59%
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--

よくある質問

Prothena Corporation PLCの䞊䜍5名の株䞻は誰ですか


Prothena Corporation PLCの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Brandon S. Smith

Prothena Corporation PLCPRTAの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Prothena Corporation PLCの株匏を保有しおいる機関は436瀟あり、保有株匏の総垂堎䟡倀は玄50.39Mで、党䜓の96.24%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-14521914.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。